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29% of moderate, 6% of severe and 1% of very severe; 7) only patients in moderate,
severe and very severe groups were considered as eligible for treatment with long-
acting maintenance therapy; and 8) 53% of annual treatment persistence rate was
applied. The ex-factory price with 24.38% of discount was used for indacaterol costs
and 5% of annual discount rate was applied on the costs. Indacaterol 150g uptake
was assumed to be: 9%, 13%, 17%, 19%, 21%; and for indacaterol 300g: 1%, 2%, 3%,
4%, 4%, over 5 years consecutively. RESULTS: The number of patients eligible for
treatment with long-acting maintenance therapy in Brazil was estimated to be
around 256,040 in the first year. The annual budget impact of indacaterol through
the years was approximately: 20M, 30M, 38M, 42M and 44M (BRL) consecutively.
CONCLUSIONS: Currently none drugs are reimbursed for COPD maintenance ther-
apy by SUS. According to this analysis, considering only the costs with indacaterol,
it should have a small impact on the Ministry of Health’s budget.
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OBJECTIVES: To assess the health care resources used and estimate the costs as-
sociated with the use of a collagen sponge coated with human fibrinogen and
thrombin compared with fibrin sealant to improve haemostasis in lung surgery and
liver resection. METHODS: A cost-analysis of the healthcare resources used with
the administration of a fibrin-based sponge and fibrin sealant was performed.
Health care resource utilisation and unit costs associated with both treatments in
lung surgery and liver resection was obtained from literature research. Costs in-
cluded for lung surgery were drug costs, preparation and administration time and
additional hospitalisation due to post-surgery pulmonary air leakage. Costs for
liver resection included drug costs, preparation and administration time, drainage
and hospitalisation days at ward or an intensive care unit. Drug costs were ob-
tained from Spanish medication databases. All costs were referred to EUR 2010.
Based on the healthcare resource use the mean cost per patient for each treatment
was estimated. A two-way sensitivity analysis was performed determining mini-
mum and maximum mean costs per patient. RESULTS: Mean drug costs for the
fibrin-based sponge and fibrin sealant in lung surgery resulted in €275 and €345,
respectively. Total treatment costs per patient were estimated at €376 and at €509
for the fibrin-based sponge and fibrin sealant. In liver resection mean drug costs
resulted in €550 for the fibrin-based sponge and in €690 for fibrin sealant, respec-
tively. The associated total treatment costs per patient added up to approximately
€5725 for the fibrin-based sponge and €6148 for fibrin sealant. CONCLUSIONS: The
use of a fibrin-based sponge showed benefits over the use of fibrin sealant in lung
surgery and liver resection. Less use of health care resources with the application of
fibrin-based sponges versus fibrin sealant resulted in lower associated treatment
costs per patient.
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OBJECTIVES: Earlier research has shown that Hand Eczema (HE) is often work-
related, widespread, potentially disabling and costly, but often misdiagnosed and
mistreated. Severe Chronic Hand Eczema (CHE) can be particularly burdensome,
especially among severe patients refractory to therapy. We assessed cost-of-illness
of severe CHE patients refractory to topical potent corticosteroids and their prev-
alence among HE patients accessing dermatology centres. METHODS: a naturalis-
tic, multicentre study was conducted in 14 Italian dermatology centers. HE patients
aged 18 years, consecutively accessing the participating centers through a
6-month period were enrolled. Socio-demographic and clinical data were collected
for all patients, while direct, indirect costs and HRQol data were collected on severe
refractory CHE patients. HRQoL was collected with the EQ-5D and the condition-
specific Dermatology-Life-Quality-Index (DLQI, having a summary score ranging
from 0 to 30, higher score corresponds to more impaired HRQoL). Direct and indi-
rect costs data were collected through a retrospective 8-week time horizon, using
the societal perspective. RESULTS: in total 981 HE patients were enrolled (mean
ageSD39.115.1, 35.9% male), 11.0% had severe refractory CHE. DLQI meanSD
sum score was 11.36.3. With EQ-5D 96.2% of patients reported moderate or severe
pain/discomfort, 73.1% problems with usual activities, 55.8% anxiety/depression
and 52.9% problems with self-care. VAS meanSD60.423.3. On average hospi-
talizations cost 67.3€/patient-month, travels cost 43.4€/patient-month, specialist
visits cost 41.0€/patient-month, other products (gloves, gauze bandage, vacuum
cleaner, cosmetics) cost 27.2€/patient-month, diagnostic exams cost 19.6€/patient-
month, non pharmacological therapy (emollients, galenic products, soap, UV-ther-
apy) cost 18.7€/patient-month, pharmacological therapy cost 18.2€/patient-month.
Patients lost on average 4.9 workdays/patient-month for reasons attributable to
their disease. CONCLUSIONS: Approximately one tenth of HE patients accessing
dermatology centers have severe refractory CHE. These generate high costs to
manage their condition, and have a significant productivity loss and a poor HRQoL.
An appropriate diagnosis and treatment is necessary to efficiently manage the
disease.
PRS18
ECONOMIC BURDEN OF CYSTIC FIBROSIS IN THE US: COSTS OF CARE BY
DISEASE SEVERITY AND AGE
Becker CC1, Clements K2, DeLong K2, Harrow B1, O’Sullivan A2
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA, 2OptumInsight, Eden Prarie, MN,
USA
Cystic fibrosis (CF) is a genetic disease characterized by progressive lung disease. In
the US, the median age of death is 27 years. Published studies of the cost of CF by
severity are outdated and do not report costs stratified jointly by age and FEV1.
OBJECTIVES: To gain understanding of the current economic burden of disease, we
estimated the cost of CF by severity and age group. METHODS: We used an admin-
istrative claims database from a large US health plan to estimate mean annual total
costs for patients with CF by age category (in 5-year increments) for patients ages 5
and older from 2004 to 2008. As claims data do not contain information on FEV1, we
derived the proportions of patients with mild (FEV1 70% predicted), moderate
(40-69% predicted), and severe (40% predicted) CF by age category using data from
the CF Foundation Registry. We then estimated the ratios of costs for moderate and
severe patients relative to mild patients using data from Lieu et al. (1999). Finally,
we estimated treatment costs for patients with CF by age and FEV1 using propor-
tions of patients in each FEV1 category, relationships between cost and disease
severity, and costs by age from the database analysis. RESULTS: Preliminary esti-
mated annual costs of care were $30,000, $57,000, and $215,000 for patients with
mild, moderate, and severe disease, respectively. For all severity groups, costs were
highest among children 10-14 years, and decreased with increasing age through
age 45 years. Estimated annual costs of care for patients with CF ranged from
$15,600 for mild patients aged 40-44 years to $343,900 for severe patients aged 10-14
years. CONCLUSIONS: Annual costs of CF care are highly variable by age and dis-
ease severity. Interventions that keep patients out of the severe disease state may
save costs.
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OBJECTIVES: Current asthma management guidelines are based on the level of
asthma control. This study was designed to estimate quality of life and health care
costs according to the patients’ level of asthma control in France and in Spain in
real-life setting.METHODS:On a 1-month and a 3-months period. An observational
retrospective bottom-up cost of illness study (XX2113553) was conducted simulta-
neously in both countries among adults with asthma. Patients were recruited by
samples of general practitioners during four quarterly waves throughout the year
2010 avoiding thus a seasonal bias. Asthma control was evaluated using the auto-
test Asthma Control Test (ACTTM) for a one month period and 2009 GINA’s asthma
control criteria for a three months period. Quality of life (QoL) was assessed using
EQ-5D profile. Costs (direct and indirect) were evaluated from a societal
perspective. RESULTS: A total of 2671 patients (France: 1154; Spain: 1517) were
enrolled in the survey. Asthma was determined to be well-controlled (ACT  20) in
54.2% [IC 95%: 50.9% - 57.7%] and 58.8% [IC95: 56.2% - 61.3%] of French and Spanish
patients respectively. In both countries, average EQ-5D scores were higher for pa-
tients with well-controlled asthma (France: 0.9 vs. 0.7, p0.0001; Spain: 0.9 vs. 0.6,
p0.0001). Total costs of asthma varied accordingly to asthma control in both
countries. The average total cost (Euros/month/patient) of well-controlled asthma
was 57 € (467) in France and 82 € (171) in Spain compared with 111 € (618)
(p0.0001) and 221 € (323) (p0.0001) respectively for not well-controlled asthma.
Similar variations were observed using the GINA’s criteria on a 3-months period.
CONCLUSIONS: Results suggested that a poor asthma control is associated with
higher costs and lower QoL in patients with asthma in both countries. Improving
the control of asthma could eventually be associated to a decrease of the burden of
asthma.
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OBJECTIVES: To examine the relationship between costs and severity of COPD, and
to up-date the economical burden of COPD for the Swedish society.METHODS: The
study sample was identified in 2009 from earlier clinical examinations of general
population cohorts within the OLIN (Obstructive Lung Disease in Northern Sweden)
studies. A number of 993 subjects were identified as having COPD (GOLD spiromet-
ric criteria). In 2009-2010, telephone interviews on resource utilization were made
to a sample of 244 subjects, stratified by disease severity. Interviews were per-
formed quarterly to minimize the risk of recall bias. Costs were calculated by ap-
plying unit costs from 2010. The prevalence for each disease severity was multi-
plied with the mean costs in order to calculate total societal costs. Non-parametric
tests were used for testing the influence of COPD severity on costs in 2010, and
when comparing the results with a previous study in 1999. RESULTS: A highly
significant relationship was found between disease severity and costs. The mean
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annual total cost per subject in relation to disease severity (GOLD) was: €783 (mild),
€2,567 (moderate), €6,818 (severe), and €19,927 (very severe). Indirect costs were
higher than direct costs in all severity stages. For direct costs, main cost drivers
were hospitalizations in severe and very severe disease, and drugs in mild and
moderate COPD, respectively. The main cost driver in indirect costs was produc-
tivity loss due to early retirement, except in mild disease where the driver was
sick-leave. In comparison with a similar study performed in 1999 a numerical
increase in mean annual total costs per subject was observed (ns). The total costs of
COPD in 2010 could be estimated to about €1212-1469 million, with indirect costs
accounting for about 70% of the total costs. CONCLUSIONS: The costs of COPD are
still high in Sweden, and the costs increase considerably by disease severity.
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OBJECTIVES:This study aimed to assess the economical impact of the CAP patients
identified through the study period. METHODS: Retrospective review of medical
records of all patients 18 years old diagnosed with CAP from January 1, 2008 to
December 31, 2009 belonging to Badalona (population  18 years: 90,315) and at-
tended by 6 primary care centres and 2 hospitals (68,274 patients seen throughout
the study period, 6 months). Economical analysis (resource utilization and direct/
indirect associated cost) is presented. Statistical analysis was performed through a
regression model and Bonferoni-adjusted ANCOVA; p0.05. RESULTS: Among the
581 patients identified [55.6% males, mean age 57.5 (SD 19,1)], 41.5% (241) were
hospitalized. Total cost per patient was 1365.97€ (85.2% related to health care direct
costs and 14.8% to non-health care costs due to sick leaves). Ambulatory care
accounted for 154.24€ (13.25%) and hospital care 1010.25€ (86.75%) of the direct
costs; p0.001. Greater impact was due to hospitalization length of stay (71.47%),
primary care pharmacological costs (13.24%) and specialist visits (11.42%). CAP
costs were related to age (r0.303); Fine scale score (r0.437) and re-hospitalization
(r0.667); p0.001. Overall cost per patient increased with age (1138€ in patients
65 year-old vs. 1716€ in  65 year-old; p0.001). CONCLUSIONS: CAP is still asso-
ciated with high economic burden in our country which is mainly due to hospital
care cost (almost one out of two patients were hospitalized). New preventive mea-
sures under development could reduce this impact.
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OBJECTIVES: The first official data on COPD prevalence, morbidity and mortality in
Ukraine were introduced in 2009 report of National Center of Medical Statistics
(2010). Nevertheless, there were no information on a number of specialists’ con-
sultations, a number of disability days and hospitalizations’ frequency in Ukrai-
nian COPD patient cohort. METHODS: Real-life 12 previous month’s data from the
personal medical cards (90%) and interview-lists (10%) of II-III severity stage COPD
patients were analyzed retrospectively. The study was conducted in three regional
clinical centers Bila-Tserkva (Kiev region), Ivano-Frankivsk, Lutsk (Volyn’ region).
Costs of COPD were calculated through the analysis of a number of GPs’ and pul-
monologists’ consultations, a number of lost working days due to COPD, and COPD
related hospitalizations frequency during the last 12 months. Direct medical costs
included outpatient costs (specialists’ consultations, control spirometry once a
year) and inpatient costs (diagnostic measures and hospital-service costs), indirect
costs included productivity loss (absenteeism and presenteeism) and disability
compensations. The 2010-2011 medical service inflation (11.45%), salary growth
rate (25%), social tax (18.6%) and Value Added Tax (17%) discounted the calcula-
tions. Exchange rate: 1EUR  11.42UAH on 18.06.2011. RESULTS: The total study
sample contained 132 patients, aged from 24 to 65 (mean age 49.4910.02), males -
60.61 %. The number of GPs’ and Pulmonologists’ consultations per COPD patient
was 2.63 and 1.18 per year respectively. The number of lost working days due to
COPD was 12.63 per patient annually and a frequency of COPD related hospitaliza-
tions was 0.56 per 12 months. The total COPD costs in Ukraine in 2009 were
€38870506 (103.03 per patient) with €28448213 (73.8%) direct medical costs and
€10422293 (26.82%) indirect costs. CONCLUSIONS: The pilot study results showed
that costs per COPD patient in Ukraine are large and could correspond with costs in
several EU countries. Nevertheless, COPD in Ukraine is underdiagnosed and under-
estimated.
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OBJECTIVES: Cystic fibrosis (CF) is an inherited disease that leads to progressive
damage to the respiratory system, the digestive system, and other organs. Medical
care utilization for patients with CF can be substantial. Recent studies of privately
insured patients with CF in the US have been fairly consistent in their estimates of
annual costs for the average or median patient with CF. However, the variation in
cost is considerable and those patients in the tail of the distribution are also those
with the most severe disease. METHODS: A national employer based claims data-
base for the years 2004 to 2008 was used to identify patients with a valid CF diag-
nosis using multiple criteria. There were a total of 5019 unique patients with CF
who had at least 1 year of continuous enrollment in the health plan. Annual all
cause costs were calculated in total and by different settings and type of cost. The
distribution of total costs was examined and the top 2.5 percentile (111 patients)
were identified as high cost users. RESULTS: While the average annual cost was
approximately $50,000 for patients in our data, the average for the high cost users
was over tenfold higher and ranged between $270,000 and $3.1 million. The vast
majority of these costs were for inpatient stays with the average number of days
spent in the hospital of 87 days. CONCLUSIONS: In this study we used a US admin-
istrative claims database to take a closer look at the most resource intensive pa-
tients with CF. A greater understanding of this group can help inform stakeholders
of the level of expenses to be incurred in the treatment of severe illness and aid in
cost-analysis of treatments.
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OBJECTIVES: This study aimed to assess the economical impact of the hospitalized
CAP patients identified through the study period. METHODS: Retrospective review
of medical records of all patients18 years old diagnosed with CAP from January 1,
2008 to December 31, 2009 belonging to Badalona (population  18 years: 90,315)
and attended by 6 primary care centres and 2 hospitals (68,274 patients seen
throughout the study period). Economical analysis of hospitalized CAP (resource
utilization and direct/indirect associated cost) is presented. Statistical analysis was
performed through a regression model and Bonferoni-adjusted ANCOVA; p0.05.
RESULTS: Among the 518 patients diagnosed with CAP included, 241 were hospi-
talized (41.5%), mean age 66.6 (SD 16.4) years-old, 55.6% males. Adjusted mean total
cost per patient was 2,332.4€ (sick leaves: 191.6€ and health care costs: 2,140.8€).
Healthcare cost was mainly caused by hospital length of stay and specialist visits
costs. Likelihood of inpatient admission increased with liver disease (OR5.9),
stroke (OR3.6), dementia (OR3.5), COPD (OR2.9), diabetes mellitus (OR1.9)
and age (OR 1.1); p0.002. Patient suffering from these co-morbidities (except
dementia) had higher hospital related costs: liver disease (2896.6€); stroke (2960.2€),
COPD (2701.9€) and diabetes mellitus (3,057.7€); p0.001. Direct hospital costs per
patient increased with patient age (805€ in patients 65 year-old vs. 1,716€ in  65
year-old; p0.001). Streptococcus pneumoniae was the most prevalent pathogen
identified [82/114 culture-positive inpatients (71.9%)]. Patients with confirmed
pneumococcal pneumonia had greater overall mean cost (2864.7€ vs. 2259.8€;
p0.041) and healthcare cost (2722.1€ vs. 2,153.6€; p0.047) than those
not-confirmed. CONCLUSIONS: CAP caused great hospital resource utilization,
mainly due to hospitalization days. Those patients older and/or suffering from
co-morbidities had greater likelihood for inpatient admission and higher hospital
related costs.
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OBJECTIVES: To review published evidence on the economic and humanistic
(health related quality of life (HRQoL)) burden of dyspnoea in patients with chronic
obstructive pulmonary disease (COPD). METHODS: A systematic literature search
was performed using PubMed and Embase databases. Search terms identified stud-
ies on economic and humanistic burden of dyspnoea in patients with COPD pub-
lished since 2000 in English.RESULTS:Two articles for economic burden and six for
humanistic burden were identified. The economic studies used different method-
ology; one a cohort study and another chart review. Both studies showed that
dyspnoea within COPD is associated with higher costs. Five quantitative and one
qualitative study were identified for humanistic burden. The quantitative studies
concluded there is a correlation between dyspnoea and QoL. Although consider-
able variation was observed around the parameters used to define dyspnoea, in-
cluding forced expiratory volume in one second (FEV1) forced vital capacity (FVC),
baseline dyspnoea index (BDI) and transitional dyspnoea index (TDI) and instru-
ments used to assess QoL, including the World Health Organisation quality of life –
BREF (WHOQOL-BREF), Borg scale and chronic respiratory disease questionnaire
(CRQ). The qualitative study was based on interviews. Patients identified breath-
lessness as the worst COPD symptom, affecting nutritional intake and an associa-
tion with anxiety. Overall, humanistic burden studies showed dyspnoea has a
significant impact on the QoL. The main limitations of the reviewed studies were
variation in instruments used to assess QoL and dyspnoea and small sample size
(range: n10-n130). CONCLUSIONS: Studies identified in this review varied in
methodological approach and were based on relatively small patient populations.
The findings of this review suggest dyspnoea may be an important predictor of
health related quality of life and economic burden in COPD. There are significant
limitations in the current evidence base, further research is required before firmer
conclusions can be drawn.
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